Active human VEGF Receptor 2 full length protein (ab42614)
- Product nameActive human VEGF Receptor 2 full length proteinSee all VEGF Receptor 2 proteins and peptides ...
- Amino Acid Sequence
- Amino acids805 to 1356
Our Abpromise guarantee covers the use of ab42614 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
- Biological activity40 U/µg. One unit is defined as the amount of enzyme that will transfer 1 pmol phosphate to Tyr substrate per minute at pH 7.4 and 30°C. Assay buffer: 50 mM HEPES, pH 7.4, 3 mM MgCl2, 3 mM MnCl2, 1 mM DTT, 3 µM Na-orthovanadate, 0.5 mM ATP, 30 µg/ml Poly (Glu:Tyr)4:1 substrate and 1 µg/ml recombinant VEGF Receptor 2.
- Purity> 90
% by SDS-PAGE.
- Additional NotesThis protein was expressed using a Baculovirus infected Sf9 cell expression system.
- Concentration information loading...
Preparation and Storage
- Stability and Storage
Aliquot and store at -80°C. Avoid repeated freeze / thaw cycles.
Constituents: 50% Glycerol, 0.05% Tween 20, 3mM DTT, 25mM Tris HCl, 100mM Sodium chloride, 10mM Reduced glutathione, pH 8
This product is an active protein and may elicit a biological response in vivo, handle with caution.
- CD309 antigen
- Fetal liver kinase 1
- Kinase insert domain receptor
- Kinase insert domain receptor (a type III receptor tyrosine kinase)
- Protein tyrosine kinase receptor FLK1
- Protein-tyrosine kinase receptor flk-1
- Tyrosine kinase growth factor receptor
- Vascular endothelial growth factor receptor 2
- VEGFR 2
- FunctionReceptor for VEGF or VEGFC. Has a tyrosine-protein kinase activity. The VEGF-kinase ligand/receptor signaling system plays a key role in vascular development and regulation of vascular permeability. In case of HIV-1 infection, the interaction with extracellular viral Tat protein seems to enhance angiogenesis in Kaposi's sarcoma lesions.
- Involvement in diseaseDefects in KDR are associated with susceptibility to hemangioma capillary infantile (HCI) [MIM:602089]. HCI are benign, highly proliferative lesions involving aberrant localized growth of capillary endothelium. They are the most common tumor of infancy, occurring in up to 10% of all births. Hemangiomas tend to appear shortly after birth and show rapid neonatal growth for up to 12 months characterized by endothelial hypercellularity and increased numbers of mast cells. This phase is followed by slow involution at a rate of about 10% per year and replacement by fibrofatty stroma.
- Sequence similaritiesBelongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily.
Contains 7 Ig-like C2-type (immunoglobulin-like) domains.
Contains 1 protein kinase domain.
modificationsPhosphorylated. Dephosphorylated by PTPRB. Dephosphorylated by PTPRJ at Tyr-951, Tyr-996, Tyr-1054, Tyr-1059, Tyr-1175 and Tyr-1214.
- Cellular localizationMembrane.
References for Active human VEGF Receptor 2 full length protein (ab42614)
ab42614 has not yet been referenced specifically in any publications.